Health Catalyst (HCAT) Financials

$3.87 +0.12 (+3.20%)

As of 03:14 PM Eastern

Annual Income Statements for Health Catalyst

This table shows Health Catalyst's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-137	-118	-70
Consolidated Net Income / (Loss)	-137	-118	-70
Net Income / (Loss) Continuing Operations	-137	-118	-70
Total Pre-Tax Income	-142	-118	-69
Total Operating Income	-140	-127	-70
Total Gross Profit	133	132	141
Total Revenue	276	296	307
Operating Revenue	276	296	307
Total Cost of Revenue	143	164	166
Operating Cost of Revenue	143	164	166
Total Operating Expenses	273	259	211
Selling, General & Admin Expense	62	77	57
Marketing Expense	88	67	54
Research & Development Expense	76	73	58
Depreciation Expense	48	42	41
Total Other Income / (Expense), net	-1.68	9.11	0.64
Interest & Investment Income	-1.68	9.11	0.64
Income Tax Expense	-4.28	0.36	0.33
Basic Earnings per Share	($2.56)	($2.09)	($1.15)
Weighted Average Basic Shares Outstanding	53.72M	56.42M	60.18M
Diluted Earnings per Share	($2.63)	($2.09)	($1.15)
Weighted Average Diluted Shares Outstanding	54.08M	56.42M	60.18M
Weighted Average Basic & Diluted Shares Outstanding	55.81M	58.56M	70.21M

This table shows Health Catalyst's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-46	-36	-33	-33	-22	-30	-21	-14	-15	-21
Consolidated Net Income / (Loss)	-46	-36	-33	-33	-22	-30	-21	-14	-15	-21
Net Income / (Loss) Continuing Operations	-46	-36	-33	-33	-22	-30	-21	-14	-15	-21
Total Pre-Tax Income	-46	-36	-33	-33	-22	-30	-20	-13	-15	-20
Total Operating Income	-46	-37	-35	-35	-25	-33	-23	-16	-14	-18
Total Gross Profit	32	31	36	34	32	31	36	36	34	35
Total Revenue	68	69	74	73	74	75	75	76	76	80
Operating Revenue	68	69	74	73	74	75	75	76	76	80
Total Cost of Revenue	36	38	38	39	42	45	39	40	42	45
Operating Cost of Revenue	36	38	38	39	42	45	39	40	42	45
Total Operating Expenses	78	68	70	68	57	63	59	52	48	52
Selling, General & Admin Expense	19	16	24	24	14	15	15	14	12	16
Marketing Expense	25	20	19	16	15	17	19	13	11	11
Research & Development Expense	21	20	17	18	18	20	15	14	14	15
Depreciation Expense	12	12	11	11	10	10	11	11	9.98	10
Total Other Income / (Expense), net	0.14	1.02	1.79	2.09	2.61	2.62	2.34	2.36	-1.51	-2.55
Interest & Investment Income	-	-	1.79	2.09	2.61	2.62	2.34	2.36	-1.51	-2.55
Income Tax Expense	0.16	0.06	0.07	0.09	0.06	0.14	0.11	0.07	-0.48	0.63
Basic Earnings per Share	($0.84)	($0.68)	($0.60)	($0.58)	($0.39)	($0.52)	($0.35)	($0.23)	($0.24)	($0.33)
Weighted Average Basic Shares Outstanding	54.30M	53.72M	55.48M	55.98M	56.71M	56.42M	58.59M	59.30M	60.44M	60.18M
Diluted Earnings per Share	($0.84)	($0.63)	($0.60)	($0.58)	($0.39)	($0.52)	($0.35)	($0.23)	($0.24)	($0.33)
Weighted Average Diluted Shares Outstanding	54.30M	54.08M	55.48M	55.98M	56.71M	56.42M	58.59M	59.30M	60.44M	60.18M
Weighted Average Basic & Diluted Shares Outstanding	54.75M	55.81M	56.26M	56.96M	57.55M	58.56M	59.03M	60.47M	60.85M	70.21M

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-77	-10	143
Net Cash From Operating Activities	-35	-33	15
Net Cash From Continuing Operating Activities	-35	-33	15
Net Income / (Loss) Continuing Operations	-137	-118	-70
Consolidated Net Income / (Loss)	-137	-118	-70
Depreciation Expense	48	42	41
Amortization Expense	-0.74	-8.21	-1.50
Non-Cash Adjustments To Reconcile Net Income	78	65	46
Changes in Operating Assets and Liabilities, net	-23	-14	-2.08
Net Cash From Investing Activities	-39	20	-23
Net Cash From Continuing Investing Activities	-39	20	-23
Purchase of Property, Plant & Equipment	-2.17	-1.24	-1.62
Acquisitions	-30	-13	-81
Purchase of Investments	-309	-291	-168
Sale of Property, Plant & Equipment	0.03	0.03	0.01
Sale and/or Maturity of Investments	315	337	242
Other Investing Activities, net	-13	-12	-14
Net Cash From Financing Activities	-2.61	2.73	152
Net Cash From Continuing Financing Activities	-2.61	2.73	152
Repayment of Debt	0.00	0.00	-3.11
Repurchase of Common Equity	-8.39	-1.81	0.00
Issuance of Debt	0.00	0.00	152
Issuance of Common Equity	3.15	3.59	2.41
Other Financing Activities, net	2.63	0.95	0.17
Effect of Exchange Rate Changes	-0.01	0.02	-0.03
Cash Interest Paid	5.75	5.75	10
Cash Income Taxes Paid	0.30	0.27	0.27

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-53	-7.91	17	-18	-21	11	95	0.53	126	-79
Net Cash From Operating Activities	-12	-15	-5.58	-12	3.12	-19	10	1.61	6.21	-3.53
Net Cash From Continuing Operating Activities	-12	-15	-5.58	-12	3.12	-19	10	1.61	6.21	-3.53
Net Income / (Loss) Continuing Operations	-46	-36	-33	-33	-22	-30	-21	-14	-15	-21
Consolidated Net Income / (Loss)	-46	-36	-33	-33	-22	-30	-21	-14	-15	-21
Depreciation Expense	12	12	11	11	10	10	11	11	9.98	10
Amortization Expense	-0.64	-1.25	-1.60	-1.64	-2.44	-2.53	-1.59	-0.80	0.57	0.32
Non-Cash Adjustments To Reconcile Net Income	23	16	16	18	15	15	16	11	10	9.29
Changes in Operating Assets and Liabilities, net	-1.36	-5.83	2.06	-6.15	2.33	-12	5.69	-5.38	0.33	-2.73
Net Cash From Investing Activities	-33	6.26	23	-7.42	-25	30	84	-1.78	7.65	-113
Net Cash From Continuing Investing Activities	-33	6.26	23	-7.42	-25	30	84	-1.78	7.65	-113
Purchase of Property, Plant & Equipment	-1.19	-0.42	-0.43	-0.41	-0.15	-0.26	-0.21	-0.29	-0.71	-0.41
Acquisitions	-0.02	-0.94	-0.10	-0.87	-0.02	-12	-0.08	-19	-36	-25
Purchase of Investments	-114	-34	-81	-84	-89	-36	-50	-	-	-118
Sale of Property, Plant & Equipment	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Sale and/or Maturity of Investments	85	45	107	82	68	81	137	21	48	36
Other Investing Activities, net	-3.00	-2.96	-2.86	-3.53	-2.94	-2.63	-2.53	-3.76	-3.57	-4.42
Net Cash From Financing Activities	-7.54	0.64	0.09	1.20	1.04	0.40	0.86	0.70	112	38
Net Cash From Continuing Financing Activities	-7.54	0.64	0.09	1.20	1.04	0.40	0.86	0.70	112	38
Repayment of Debt	-	-	-	-	-	-	-	-	-	0.54
Issuance of Debt	-	-	-	-	-	-	-	-	-	37
Issuance of Common Equity	1.03	0.60	1.17	1.03	1.00	0.38	0.84	0.59	0.63	0.35
Effect of Exchange Rate Changes	-0.01	0.02	0.01	-0.00	-0.02	0.03	-0.02	-0.00	0.08	-0.10

This table presents Health Catalyst's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	752	702	859
Total Current Assets	428	393	466
Cash & Equivalents	116	106	250
Short-Term Investments	247	211	142
Accounts Receivable	48	60	57
Prepaid Expenses	16	15	16
Plant, Property, & Equipment, net	26	26	29
Total Noncurrent Assets	299	283	364
Goodwill	186	191	260
Intangible Assets	92	73	86
Other Noncurrent Operating Assets	20	19	18
Total Liabilities & Shareholders' Equity	752	702	859
Total Liabilities	327	335	494
Total Current Liabilities	83	89	326
Short-Term Debt	-	0.00	231
Accounts Payable	4.42	6.64	11
Accrued Expenses	20	23	26
Current Deferred Revenue	55	56	53
Other Current Liabilities	3.43	3.36	3.61
Total Noncurrent Liabilities	245	246	168
Long-Term Debt	227	228	151
Noncurrent Deferred Revenue	0.11	0.08	0.25
Other Noncurrent Operating Liabilities	18	18	16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	425	367	365
Total Preferred & Common Equity	425	367	365
Preferred Stock	0.00	0.00	0.00
Total Common Equity	425	367	365
Common Stock	1,425	1,484	1,553
Retained Earnings	-999	-1,117	-1,187
Accumulated Other Comprehensive Income / (Loss)	-0.65	0.03	-0.84

This table presents Health Catalyst's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	776	752	723	713	695	692	813
Total Current Assets	443	435	411	408	397	376	457
Cash & Equivalents	124	133	116	95	201	202	328
Short-Term Investments	256	223	228	253	126	106	59
Accounts Receivable	50	62	52	46	54	55	52
Prepaid Expenses	14	16	15	15	15	13	19
Plant, Property, & Equipment, net	25	26	26	26	25	26	28
Total Noncurrent Assets	308	291	286	278	273	290	328
Goodwill	186	186	186	186	191	206	234
Intangible Assets	101	84	79	72	66	67	76
Other Noncurrent Operating Assets	21	21	21	20	16	17	17
Total Liabilities & Shareholders' Equity	776	752	723	713	695	692	813
Total Liabilities	336	347	333	331	338	335	458
Total Current Liabilities	91	102	87	84	92	318	324
Short-Term Debt	0.00	-	-	-	3.35	0.89	230
Accounts Payable	6.82	9.24	7.97	6.33	5.70	11	14
Accrued Expenses	24	24	16	21	20	18	24
Current Deferred Revenue	56	66	60	53	64	56	52
Other Current Liabilities	3.46	3.39	3.47	3.40	-	232	3.33
Total Noncurrent Liabilities	245	245	246	246	246	17	134
Long-Term Debt	226	227	227	228	228	0.00	115
Noncurrent Deferred Revenue	0.32	0.19	0.09	0.31	0.08	0.05	0.26
Other Noncurrent Operating Liabilities	19	18	19	18	0.09	17	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	440	405	390	382	357	357	355
Total Preferred & Common Equity	440	405	390	382	357	357	355
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	440	405	390	382	357	357	355
Common Stock	1,404	1,438	1,455	1,469	1,495	1,508	1,521
Retained Earnings	-963	-1,032	-1,065	-1,087	-1,138	-1,151	-1,166
Accumulated Other Comprehensive Income / (Loss)	-0.88	-0.30	-0.20	-0.17	-0.12	-0.16	-0.11

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	14.18%	7.13%	3.60%
EBITDA Growth	0.57%	-0.47%	67.83%
EBIT Growth	2.54%	9.36%	44.99%
NOPAT Growth	2.54%	9.36%	44.99%
Net Income Growth	10.32%	14.01%	41.17%
EPS Growth	18.58%	20.53%	44.98%
Operating Cash Flow Growth	-52.53%	6.21%	144.01%
Free Cash Flow Firm Growth	29.29%	36.79%	-63.06%
Invested Capital Growth	9.67%	-3.76%	28.26%
Revenue Q/Q Growth	1.64%	2.04%	1.50%
EBITDA Q/Q Growth	4.03%	1.41%	37.72%
EBIT Q/Q Growth	5.42%	3.03%	17.96%
NOPAT Q/Q Growth	5.42%	3.03%	17.96%
Net Income Q/Q Growth	8.77%	4.43%	12.18%
EPS Q/Q Growth	11.15%	5.00%	14.18%
Operating Cash Flow Q/Q Growth	-16.70%	-14.62%	1,624.50%
Free Cash Flow Firm Q/Q Growth	57.88%	-14.75%	-15.61%
Invested Capital Q/Q Growth	0.72%	5.67%	13.67%
Profitability Metrics	-	-	-
Gross Margin	48.21%	44.55%	45.92%
EBITDA Margin	-33.47%	-31.39%	-9.74%
Operating Margin	-50.68%	-42.88%	-22.77%
EBIT Margin	-50.68%	-42.88%	-22.77%
Profit (Net Income) Margin	-49.74%	-39.92%	-22.67%
Tax Burden Percent	96.98%	100.30%	100.48%
Interest Burden Percent	101.20%	92.82%	99.09%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-35.59%	-31.43%	-15.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-15.72%	-5.56%	26.11%
Return on Net Nonoperating Assets (RNNOA)	6.58%	1.59%	-3.54%
Return on Equity (ROE)	-29.02%	-29.84%	-18.99%
Cash Return on Invested Capital (CROIC)	-44.82%	-27.60%	-40.20%
Operating Return on Assets (OROA)	-17.67%	-17.45%	-8.95%
Return on Assets (ROA)	-17.34%	-16.25%	-8.91%
Return on Common Equity (ROCE)	-29.02%	-29.84%	-18.99%
Return on Equity Simple (ROE_SIMPLE)	-32.33%	-32.20%	-19.03%
Net Operating Profit after Tax (NOPAT)	-98	-89	-49
NOPAT Margin	-35.48%	-30.02%	-15.94%
Net Nonoperating Expense Percent (NNEP)	-19.88%	-25.87%	-41.55%
Return On Investment Capital (ROIC_SIMPLE)	-15.04%	-14.93%	-6.54%
Cost of Revenue to Revenue	51.79%	55.45%	54.08%
SG&A Expenses to Revenue	22.34%	25.87%	18.53%
R&D to Revenue	27.40%	24.54%	18.90%
Operating Expenses to Revenue	98.90%	87.43%	68.69%
Earnings before Interest and Taxes (EBIT)	-140	-127	-70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-92	-93	-30
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.37	1.45	1.18
Price to Tangible Book Value (P/TBV)	3.96	5.18	22.18
Price to Revenue (P/Rev)	2.11	1.80	1.40
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.55	1.60	1.18
Enterprise Value to Revenue (EV/Rev)	1.61	1.50	1.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	28.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.53	0.62	1.05
Long-Term Debt to Equity	0.53	0.62	0.41
Financial Leverage	-0.42	-0.29	-0.14
Leverage Ratio	1.67	1.84	2.13
Compound Leverage Factor	1.69	1.70	2.11
Debt to Total Capital	34.77%	38.33%	51.15%
Short-Term Debt to Total Capital	0.00%	0.00%	30.92%
Long-Term Debt to Total Capital	34.77%	38.33%	20.22%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.23%	61.67%	48.85%
Debt to EBITDA	-2.45	-2.46	-12.80
Net Debt to EBITDA	1.48	0.97	0.32
Long-Term Debt to EBITDA	-2.45	-2.46	-5.06
Debt to NOPAT	-2.31	-2.57	-7.83
Net Debt to NOPAT	1.40	1.01	0.20
Long-Term Debt to NOPAT	-2.31	-2.57	-3.09
Altman Z-Score	-0.49	-0.93	-1.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.18	4.42	1.43
Quick Ratio	4.99	4.25	1.38
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-123	-78	-127
Operating Cash Flow to CapEx	-1,649.67%	-2,745.23%	908.23%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.35	0.41	0.39
Accounts Receivable Turnover	5.71	5.47	5.22
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	11.22	11.46	11.13
Accounts Payable Turnover	31.38	29.66	18.35
Days Sales Outstanding (DSO)	63.93	66.76	69.93
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	11.63	12.31	19.89
Cash Conversion Cycle (CCC)	52.30	54.46	50.03
Capital & Investment Metrics	-	-	-
Invested Capital	288	277	356
Invested Capital Turnover	1.00	1.05	0.97
Increase / (Decrease) in Invested Capital	25	-11	78
Enterprise Value (EV)	445	443	421
Market Capitalization	582	533	430
Book Value per Share	$7.76	$6.38	$6.00
Tangible Book Value per Share	$2.68	$1.79	$0.32
Total Capital	652	595	748
Total Debt	227	228	382
Total Long-Term Debt	227	228	151
Net Debt	-137	-90	-9.64
Capital Expenditures (CapEx)	2.14	1.21	1.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-13	-21
Debt-free Net Working Capital (DFNWC)	345	304	371
Net Working Capital (NWC)	345	304	140
Net Nonoperating Expense (NNE)	39	29	21
Net Nonoperating Obligations (NNO)	-137	-90	-9.64
Total Depreciation and Amortization (D&A)	48	34	40
Debt-free, Cash-free Net Working Capital to Revenue	-6.59%	-4.52%	-6.86%
Debt-free Net Working Capital to Revenue	125.00%	102.85%	121.01%
Net Working Capital to Revenue	125.00%	102.85%	45.60%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.56)	($2.09)	($1.15)
Adjusted Weighted Average Basic Shares Outstanding	53.72M	56.42M	60.18M
Adjusted Diluted Earnings per Share	($2.63)	($2.09)	($1.15)
Adjusted Weighted Average Diluted Shares Outstanding	54.08M	56.42M	60.18M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	55.81M	58.56M	70.21M
Normalized Net Operating Profit after Tax (NOPAT)	-98	-89	-49
Normalized NOPAT Margin	-35.48%	-30.02%	-15.94%
Pre Tax Income Margin	-51.29%	-39.80%	-22.56%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-6.11%	-1.53%	0.00%

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.72%	6.87%	8.49%	3.65%	7.93%	8.56%	1.16%	3.67%	3.50%	6.02%
EBITDA Growth	-19.40%	12.84%	-114.00%	-26.37%	50.48%	5.04%	45.64%	76.68%	81.37%	72.35%
EBIT Growth	-8.22%	17.92%	-43.40%	-4.30%	46.24%	10.78%	34.66%	54.34%	44.32%	46.62%
NOPAT Growth	-8.22%	17.92%	-43.40%	-4.30%	46.24%	10.78%	34.66%	54.34%	44.32%	46.62%
Net Income Growth	-14.30%	26.96%	-47.79%	2.44%	51.83%	15.29%	37.97%	58.56%	33.16%	31.80%
EPS Growth	-2.44%	34.38%	-11.11%	6.45%	53.57%	17.46%	41.67%	60.34%	38.46%	36.54%
Operating Cash Flow Growth	-124.46%	-51.62%	-581.87%	-20.86%	125.89%	-28.47%	283.98%	113.93%	99.29%	81.48%
Free Cash Flow Firm Growth	-414.54%	51.45%	93.85%	98.52%	102.90%	76.27%	-10.72%	4,884.64%	-1,036.28%	-646.75%
Invested Capital Growth	195.97%	9.67%	-2.53%	-6.75%	-8.26%	-3.76%	1.16%	-81.84%	19.23%	28.26%
Revenue Q/Q Growth	-3.23%	1.18%	6.80%	-0.89%	0.76%	1.78%	-0.48%	1.58%	0.59%	4.26%
EBITDA Q/Q Growth	-68.24%	22.52%	3.08%	-0.02%	34.07%	-48.59%	44.52%	57.09%	47.32%	-120.47%
EBIT Q/Q Growth	-37.75%	19.63%	4.98%	0.85%	29.00%	-33.38%	30.42%	30.71%	13.41%	-27.86%
NOPAT Q/Q Growth	-37.75%	19.63%	4.98%	0.85%	29.00%	-33.38%	30.42%	30.71%	13.41%	-27.86%
Net Income Q/Q Growth	-36.82%	21.76%	7.24%	1.74%	32.44%	-37.58%	32.08%	34.35%	-8.95%	-40.38%
EPS Q/Q Growth	-35.48%	25.00%	4.76%	3.33%	32.76%	-33.33%	32.69%	34.29%	-4.35%	-37.50%
Operating Cash Flow Q/Q Growth	-25.64%	-23.19%	62.35%	-107.42%	126.91%	-711.27%	153.92%	-84.30%	285.11%	-156.81%
Free Cash Flow Firm Q/Q Growth	26.35%	76.90%	66.18%	74.30%	244.32%	-289.17%	-57.82%	1,210.44%	-128.24%	-50.88%
Invested Capital Q/Q Growth	-2.43%	0.72%	-4.49%	-0.66%	-4.01%	5.67%	0.39%	-82.16%	530.17%	13.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.84%	44.90%	48.15%	46.13%	43.36%	40.63%	48.45%	47.22%	44.58%	43.58%
EBITDA Margin	-49.72%	-38.07%	-34.55%	-34.87%	-22.81%	-33.30%	-18.57%	-7.84%	-4.11%	-8.69%
Operating Margin	-66.89%	-53.13%	-47.27%	-47.28%	-33.32%	-43.66%	-30.53%	-20.83%	-17.93%	-21.98%
EBIT Margin	-66.89%	-53.13%	-47.27%	-47.28%	-33.32%	-43.66%	-30.53%	-20.83%	-17.93%	-21.98%
Profit (Net Income) Margin	-66.91%	-51.74%	-44.93%	-44.55%	-29.86%	-40.37%	-27.55%	-17.81%	-19.29%	-25.97%
Tax Burden Percent	100.34%	100.17%	100.21%	100.26%	100.27%	100.47%	100.55%	100.52%	96.88%	103.12%
Interest Burden Percent	99.69%	97.22%	94.86%	93.96%	89.39%	92.02%	89.75%	85.06%	111.06%	114.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-66.52%	-37.31%	-33.48%	-33.26%	-24.67%	-32.00%	-22.92%	-27.04%	-13.18%	-14.91%
ROIC Less NNEP Spread (ROIC-NNEP)	-62.00%	-32.24%	-28.16%	-27.53%	-21.15%	-25.51%	-18.50%	-25.88%	-6.84%	2.05%
Return on Net Nonoperating Assets (RNNOA)	38.02%	13.49%	10.44%	9.38%	7.05%	7.30%	5.07%	14.69%	1.50%	-0.28%
Return on Equity (ROE)	-28.51%	-23.82%	-23.04%	-23.89%	-17.62%	-24.70%	-17.85%	-12.35%	-11.68%	-15.19%
Cash Return on Invested Capital (CROIC)	-153.15%	-44.82%	-35.26%	-30.58%	-24.80%	-27.60%	-30.19%	96.91%	-38.26%	-40.20%
Operating Return on Assets (OROA)	-22.42%	-18.53%	-16.90%	-17.54%	-12.98%	-17.77%	-12.52%	-8.82%	-7.10%	-8.64%
Return on Assets (ROA)	-22.43%	-18.04%	-16.07%	-16.53%	-11.63%	-16.43%	-11.30%	-7.54%	-7.64%	-10.20%
Return on Common Equity (ROCE)	-28.51%	-23.82%	-23.04%	-23.89%	-17.62%	-24.70%	-17.85%	-12.35%	-11.68%	-15.19%
Return on Equity Simple (ROE_SIMPLE)	-34.23%	0.00%	-36.56%	-37.79%	-32.33%	0.00%	-29.55%	-24.21%	-22.29%	0.00%
Net Operating Profit after Tax (NOPAT)	-32	-26	-24	-24	-17	-23	-16	-11	-9.58	-12
NOPAT Margin	-46.82%	-37.19%	-33.09%	-33.10%	-23.32%	-30.57%	-21.37%	-14.58%	-12.55%	-15.39%
Net Nonoperating Expense Percent (NNEP)	-4.53%	-5.08%	-5.32%	-5.73%	-3.52%	-6.50%	-4.42%	-1.16%	-6.34%	-16.96%
Return On Investment Capital (ROIC_SIMPLE)	-	-3.95%	-	-	-	-3.86%	-	-	-	-1.64%
Cost of Revenue to Revenue	53.16%	55.10%	51.85%	53.87%	56.64%	59.37%	51.55%	52.78%	55.42%	56.42%
SG&A Expenses to Revenue	28.08%	23.35%	32.26%	32.33%	18.47%	20.55%	19.49%	18.92%	15.99%	19.70%
R&D to Revenue	30.39%	28.36%	23.13%	24.03%	23.95%	27.02%	19.90%	18.29%	18.59%	18.85%
Operating Expenses to Revenue	113.72%	98.03%	95.41%	93.42%	76.68%	84.30%	78.98%	68.05%	62.51%	65.56%
Earnings before Interest and Taxes (EBIT)	-46	-37	-35	-35	-25	-33	-23	-16	-14	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-26	-26	-26	-17	-25	-14	-5.95	-3.14	-6.91
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.21	1.37	1.61	1.80	1.51	1.45	1.21	1.06	1.39	1.18
Price to Tangible Book Value (P/TBV)	3.46	3.96	4.83	5.63	4.63	5.18	4.32	4.49	11.14	22.18
Price to Revenue (P/Rev)	1.95	2.11	2.31	2.47	1.99	1.80	1.46	1.26	1.63	1.40
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.32	1.55	1.89	2.15	1.74	1.60	1.27	1.41	1.44	1.18
Enterprise Value to Revenue (EV/Rev)	1.39	1.61	1.85	2.06	1.57	1.50	1.19	0.23	1.49	1.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.45	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.51	0.53	0.56	0.58	0.60	0.62	0.70	0.00	0.97	1.05
Long-Term Debt to Equity	0.51	0.53	0.56	0.58	0.60	0.62	0.69	0.00	0.32	0.41
Financial Leverage	-0.61	-0.42	-0.37	-0.34	-0.33	-0.29	-0.27	-0.57	-0.22	-0.14
Leverage Ratio	1.64	1.67	1.78	1.79	1.81	1.84	1.90	1.89	2.07	2.13
Compound Leverage Factor	1.63	1.63	1.69	1.68	1.62	1.69	1.70	1.61	2.30	2.44
Debt to Total Capital	33.95%	34.77%	35.90%	36.83%	37.32%	38.33%	41.06%	0.25%	49.29%	51.15%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.55%	0.25%	32.91%	30.92%
Long-Term Debt to Total Capital	33.95%	34.77%	35.90%	36.83%	37.32%	38.33%	40.51%	0.00%	16.37%	20.22%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	66.05%	65.23%	64.10%	63.17%	62.68%	61.67%	58.94%	99.75%	50.71%	48.85%
Debt to EBITDA	-2.35	-2.45	-2.14	-2.04	-2.42	-2.46	-3.06	-0.01	-7.19	-12.80
Net Debt to EBITDA	1.60	1.48	1.23	1.05	1.27	0.97	0.97	4.98	0.88	0.32
Long-Term Debt to EBITDA	-2.35	-2.45	-2.14	-2.04	-2.42	-2.46	-3.02	0.00	-2.39	-5.06
Debt to NOPAT	-2.18	-2.31	-2.15	-2.14	-2.49	-2.57	-3.10	-0.01	-5.79	-7.83
Net Debt to NOPAT	1.49	1.40	1.23	1.10	1.31	1.01	0.98	4.57	0.71	0.20
Long-Term Debt to NOPAT	-2.18	-2.31	-2.15	-2.14	-2.49	-2.57	-3.06	0.00	-1.92	-3.09
Altman Z-Score	-0.09	-0.04	-0.04	-0.02	-0.25	-0.49	-0.68	-1.20	-0.85	-0.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.87	5.18	4.24	4.74	4.85	4.42	4.31	1.18	1.41	1.43
Quick Ratio	4.72	4.99	4.09	4.57	4.67	4.25	4.14	1.14	1.36	1.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-221	-51	-17	-4.44	6.41	-12	-19	213	-60	-91
Operating Cash Flow to CapEx	-1,016.13%	-3,650.49%	-1,331.74%	-2,879.10%	2,241.01%	-7,771.84%	5,007.80%	563.64%	884.33%	-860.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.35	0.36	0.37	0.39	0.41	0.41	0.42	0.40	0.39
Accounts Receivable Turnover	5.59	5.71	5.40	5.68	6.07	5.47	5.13	5.58	6.18	5.22
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	11.81	11.22	10.99	10.81	11.34	11.46	11.61	11.59	11.19	11.13
Accounts Payable Turnover	23.96	31.38	19.51	22.27	23.99	29.66	22.00	17.76	16.06	18.35
Days Sales Outstanding (DSO)	65.28	63.93	67.62	64.21	60.18	66.76	71.17	65.37	59.05	69.93
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	15.23	11.63	18.71	16.39	15.22	12.31	16.59	20.55	22.73	19.89
Cash Conversion Cycle (CCC)	50.05	52.30	48.91	47.82	44.96	54.46	54.57	44.82	36.32	50.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	286	288	275	273	262	277	278	50	313	356
Invested Capital Turnover	1.42	1.00	1.01	1.00	1.06	1.05	1.07	1.85	1.05	0.97
Increase / (Decrease) in Invested Capital	189	25	-7.15	-20	-24	-11	3.18	-224	50	78
Enterprise Value (EV)	377	445	521	587	456	443	354	70	450	421
Market Capitalization	531	582	651	703	576	533	433	377	492	430
Book Value per Share	$8.04	$7.76	$7.26	$6.93	$6.71	$6.38	$6.10	$6.05	$5.87	$6.00
Tangible Book Value per Share	$2.80	$2.68	$2.41	$2.22	$2.18	$1.79	$1.71	$1.42	$0.73	$0.32
Total Capital	666	652	632	617	610	595	606	358	700	748
Total Debt	226	227	227	227	228	228	249	0.89	345	382
Total Long-Term Debt	226	227	227	227	228	228	246	0.00	115	151
Net Debt	-154	-137	-130	-117	-120	-90	-79	-307	-42	-9.64
Capital Expenditures (CapEx)	1.18	0.41	0.42	0.40	0.14	0.25	0.21	0.29	0.70	0.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-18	-25	-20	-23	-13	-20	-249	-23	-21
Debt-free Net Working Capital (DFNWC)	352	345	332	324	324	304	308	59	364	371
Net Working Capital (NWC)	352	345	332	324	324	304	305	58	134	140
Net Nonoperating Expense (NNE)	14	10	8.75	8.38	4.83	7.36	4.62	2.45	5.15	8.42
Net Nonoperating Obligations (NNO)	-154	-137	-130	-117	-120	-90	-79	-307	-42	-9.64
Total Depreciation and Amortization (D&A)	12	10	9.39	9.09	7.75	7.78	8.94	9.85	11	11
Debt-free, Cash-free Net Working Capital to Revenue	-10.21%	-6.59%	-8.83%	-6.90%	-8.10%	-4.52%	-6.57%	-83.25%	-7.68%	-6.86%
Debt-free Net Working Capital to Revenue	129.65%	125.00%	117.73%	113.91%	111.79%	102.85%	103.87%	19.68%	120.52%	121.01%
Net Working Capital to Revenue	129.65%	125.00%	117.73%	113.91%	111.79%	102.85%	102.74%	19.38%	44.24%	45.60%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.84)	($0.68)	($0.60)	($0.58)	($0.39)	($0.52)	($0.35)	($0.23)	($0.24)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	54.30M	53.72M	55.48M	55.98M	56.71M	56.42M	58.59M	59.30M	60.44M	60.18M
Adjusted Diluted Earnings per Share	($0.84)	($0.63)	($0.60)	($0.58)	($0.39)	($0.52)	($0.35)	($0.23)	($0.24)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	54.30M	54.08M	55.48M	55.98M	56.71M	56.42M	58.59M	59.30M	60.44M	60.18M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.75M	55.81M	56.26M	56.96M	57.55M	58.56M	59.03M	60.47M	60.85M	70.21M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-26	-24	-24	-17	-23	-16	-11	-9.58	-12
Normalized NOPAT Margin	-46.82%	-37.19%	-33.09%	-33.10%	-23.32%	-30.57%	-21.37%	-14.58%	-12.55%	-15.39%
Pre Tax Income Margin	-66.68%	-51.65%	-44.84%	-44.43%	-29.78%	-40.18%	-27.40%	-17.71%	-19.91%	-25.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-5.57%	-6.11%	-6.89%	-6.92%	-1.46%	-1.53%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Health Catalyst's Financials

When does Health Catalyst's fiscal year end?

According to the most recent income statement we have on file, Health Catalyst's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Health Catalyst's net income changed over the last 2 years?

Health Catalyst's net income appears to be on a downward trend, with a most recent value of -$69.50 million in 2024, falling from -$137.40 million in 2022. The previous period was -$118.15 million in 2023.

What is Health Catalyst's operating income?

Health Catalyst's total operating income in 2024 was -$69.81 million, based on the following breakdown:

Total Gross Profit: $140.78 million
Total Operating Expenses: $210.59 million

How has Health Catalyst revenue changed over the last 2 years?

Over the last 2 years, Health Catalyst's total revenue changed from $276.24 million in 2022 to $306.58 million in 2024, a change of 11.0%.

How much debt does Health Catalyst have?

Health Catalyst's total liabilities were at $493.72 million at the end of 2024, a 47.4% increase from 2023, and a 50.9% increase since 2022.

How much cash does Health Catalyst have?

In the past 2 years, Health Catalyst's cash and equivalents has ranged from $106.28 million in 2023 to $249.65 million in 2024, and is currently $249.65 million as of their latest financial filing in 2024.

How has Health Catalyst's book value per share changed over the last 2 years?

Over the last 2 years, Health Catalyst's book value per share changed from 7.76 in 2022 to 6.00 in 2024, a change of -22.7%.

Remove Ads

Related Companies

This page (NASDAQ:HCAT) was last updated on 4/17/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Financials

Frequently Asked Questions About Health Catalyst's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Catalyst (HCAT) Financials

Annual Income Statements for Health Catalyst

Quarterly Income Statements for Health Catalyst

Annual Cash Flow Statements for Health Catalyst

Quarterly Cash Flow Statements for Health Catalyst

Annual Balance Sheets for Health Catalyst

Quarterly Balance Sheets for Health Catalyst

Annual Metrics and Ratios for Health Catalyst

Quarterly Metrics and Ratios for Health Catalyst

Frequently Asked Questions About Health Catalyst's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools